- Home
- TNON vs EDSA Comparison
TNON vs EDSA Comparison
Compare TNON & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TNON | EDSA |
|---|---|---|
| Founded | 2012 | 2015 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.8M | 12.8M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | TNON | EDSA |
|---|---|---|
| Price | $1.06 | $1.29 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $3.00 | ★ $13.00 |
| AVG Volume (30 Days) | ★ 73.3K | 34.5K |
| Earning Date | 11-13-2025 | 12-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,233,000.00 | N/A |
| Revenue This Year | $19.56 | N/A |
| Revenue Next Year | $71.06 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.85 | $1.28 |
| 52 Week High | $5.85 | $4.49 |
Technical Indicators
Market Signals| Indicator | TNON | EDSA |
|---|---|---|
| Relative Strength Index (RSI) | 42.23 | 23.75 |
| Support Level | $1.06 | $1.43 |
| Resistance Level | $1.13 | $1.50 |
| Average True Range (ATR) | 0.04 | 0.08 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 12.00 | 4.59 |
Price Performance
Historical ComparisonAbout TNON Tenon Medical Inc.
Tenon Medical Inc is a medical device company that has developed a novel, minimally invasive approach to the sacroiliac joint (the SI Joint) using a single, robust, titanium implant for the treatment of the common types of SI Joint disorders that cause lower back pain. The Company is focused on three commercial opportunities; Primary SI Joint procedures, Revision procedures of failed SI Joint implants, and SI Joint fusion adjunct to a spine fusion construct. The company derives the majority of its revenue from sales of The Catamaran System to a limited number of clinicians.
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.